Ulsa Tech

What Ulsa Tech does

Ulsa Tech (legal name ULSA TECH, S. A. DE C. V.) is a privately held Mexican pharmaceutical company founded on June 6, 2014, and headquartered in Guadalajara, Jalisco, Mexico. The company manufactures generic injectable and oral oncological medications, positioning itself as a domestic supplier of affordable cancer drugs priced 39% below innovative alternatives. Its product portfolio spans four therapeutic areas: Clinical Oncology (adult solid tumors including breast, lung, prostate, colon, gastric, ovarian, head and neck, testicular, and glioma cancers), Hematology (multiple myeloma, leukemia, Hodgkin and non-Hodgkin lymphoma, mantle cell lymphoma), Pediatric Oncology (childhood leukemias and lymphomas), and Complement to Treatment (cardio-protective supportive care). All products are manufactured at facilities described as operating at the highest technological level for injectable and oral drug production, using raw materials from internationally certified sources and complying with international manufacturing regulations.

The company's distribution model is B2B and exclusively restricted to verified healthcare professionals and the public health sector; the product catalog is password-protected and requires health-professional credentials to access. Marketing is conducted through a content-driven website and blog focused on cancer awareness, supplemented by organic social media presence on Facebook, Twitter, and LinkedIn. No direct-to-consumer channel exists.

Ulsa Tech operates a Pharmacovigilance Unit formally recognized by COFEPRIS (Mexico's Federal Commission for the Protection against Sanitary Risks) and complies with NOM-220-SSA1-2016 pharmacovigilance requirements. The company holds Advertising Permission No. 213300201B2847. It is founder/owner-operated with no disclosed parent company, no institutional funding rounds, and no M&A activity. Headcount is reported at 51–100 employees. No revenue, AI capabilities, patents, or named end customers are disclosed in available source materials.

Name

Ulsa Tech

Legal name

ULSA TECH, S. A. DE C. V.

Website

https://ulsatech.com.mx

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

Ulsa Tech is a Mexican pharmaceutical company that manufactures generic injectable and oral oncology medications across four therapeutic areas, supplying verified healthcare professionals and the public health sector in Mexico.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Oncology pharmaceuticals
• Generic cancer drugs
• Injectable medications
• Hematology treatments
• Pharmaceutical manufacturing

Headquarters

HQ city

Guadalajara

HQ country

Mexico

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Products Sales: Manufacturing and commercialization of generic and patent pharmaceutical products for human health, including oncological medications, injectable and oral solid drugs. The company performs research, development, manufacture, elaboration, assembly and distribution of these products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Ulsa Tech is a Mexican pharmaceutical manufacturer that develops, produces, and commercializes generic oncological medications in both injectable and oral dosage forms. Its product portfolio spans four therapeutic areas — Clinical Oncology, Hematology, Pediatric Oncology, and Complement to Treatment (cardio protection) — targeting cancers including breast, lung, prostate, colon, gastric, ovarian, head and neck, testicular cancers, gliomas, multiple myeloma, leukemias, Hodgkin and non-Hodgkin lymphomas, and mantle cell lymphoma. Products are sold exclusively to verified healthcare professionals and institutional buyers through a credentialed catalog.

Product overview

Ulsa Tech is a Mexican pharmaceutical company offering a portfolio of high-specialty generic medications focused on oncology and hematology. The company's product offering comprises four therapeutic areas: Clinical Oncology (for adult cancers including breast, lung, prostate, colon, gastric, ovarian, head/neck, and testicular cancers), Hematology (for blood diseases including multiple myeloma, leukemias, and lymphomas), Pediatric Oncology (for childhood cancers including leukemias and lymphomas), and Complement to Treatment (cardio protection for cancer patients). All products are generic drugs, which are 39% more affordable than innovative alternatives, and are manufactured at international regulatory standards using certified raw materials and high technological levels for injectable and oral medications.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Oncology Products Specialized injectable and oral medications for the treatment of adult solid-tumor cancers including breast cancer, lung cancer, prostate cancer, colon cancer, gastric cancer, ovarian cancer, head and neck cancer, testicular cancer, and gliomas. Targeted at oncology prescribers and institutional buyers.
• Hematology Products Medications dedicated to the treatment of patients with blood or hematological diseases including multiple myeloma, leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and mantle cell lymphoma. Targeted at hematologists and institutional oncology buyers.
• Pediatric Oncology Products Effective treatments for the main types of cancer affecting pediatric patients, including leukemias and Hodgkin and non-Hodgkin lymphomas in children and adolescents aged 0–19 years. Targeted at pediatric oncologists and pediatric care institutions.
• Complement to Treatment (Cardio Protection) Cardio protection treatments serving as complementary therapy for cancer patients, addressing cardiovascular side effects associated with primary cancer therapy. Targeted at oncologists and supportive care providers.
• Generic Cancer Medications Line Generic drugs for cancer treatment manufactured in injectable and oral forms using raw materials from internationally certified sources, priced 39% lower than innovative cancer medications. Available to verified healthcare professionals through the company's password-protected catalog.

Quantifiable outcome

• Generic drugs are 39% cheaper than innovative cancer drugs

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Regional players

• Cipla: Cipla is a major Indian generic pharmaceutical manufacturer with a strong oncology and injectable portfolio, exporting widely to Latin American markets. It is comparable to Ulsa Tech through oncology generics and injectable manufacturing, though Cipla operates globally while Ulsa Tech is Mexico-domestic.
• Laboratorios Richmond: Laboratorios Richmond is an Argentine pharmaceutical manufacturer with oncology and specialty pharmaceutical operations serving Latin America. Comparable to Ulsa Tech through its LatAm regional oncology generics focus, though primarily based in Argentina rather than Mexico.
• Eurofarma México: Eurofarma is a leading Latin American pharmaceutical company with oncology and specialty generic operations across the region. It is comparable to Ulsa Tech through its Latin American oncology generics focus, though it operates at significantly larger scale and across multiple geographies rather than as a Mexican domestic specialist.

Direct peers

• PiSA Farmacéutica: PiSA Farmacéutica is a major Mexican pharmaceutical manufacturer with a broad portfolio including oncology and injectable generics. Both companies operate Mexican manufacturing facilities, produce injectable and oral generics, and target the institutional healthcare market through medical professional channels.
• Asofarma: Asofarma is a Mexican pharmaceutical company with a strong focus on specialty therapeutic areas including oncology. Like Ulsa Tech, it is a domestic Mexican manufacturer targeting healthcare professionals with institutional sales channels, making it one of the closest direct comparables for Mexican oncology pharma.
• Ultra Laboratorios: Ultra Laboratorios is a Mexican pharmaceutical manufacturer and the contact domain for Ulsa Tech's International Business contact, suggesting a closely related group or commercial alliance. Both companies share Mexican-domestic oncology/generic pharmaceutical manufacturing activities, making them highly comparable.

Broad incumbents

• Apotex: Apotex is one of the largest Canadian generic pharmaceutical manufacturers with oncology and injectable capabilities. It is comparable to Ulsa Tech in its generic-oncology manufacturing focus, though it serves global markets from a much larger production base.
• Viatris (Mylan): Viatris (formed via Mylan-Upjohn combination) is a major global generic and specialty pharmaceutical company with a meaningful oncology portfolio. Comparable to Ulsa Tech through its generic injectable oncology products, though at much larger scale and across global markets.
• Roche: Roche is a global pharmaceutical leader with the broadest innovator oncology portfolio (breast, lung, hematology, pediatric cancers). While Ulsa Tech explicitly positions against Roche's innovator drugs on price (39% cheaper), Roche defines the therapeutic landscape and treatment protocols Ulsa Tech's generics target.
• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with a significant oncology generics portfolio. It is comparable to Ulsa Tech through its generic-oncology focus and injectable manufacturing capabilities, but operates globally with a much broader portfolio across many therapeutic areas.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

• Xx.com/ulsa_tech
• Facebookfacebook.com/ULSATECH
• LinkedInlinkedin.com/company/ulsa-tech-sa-de-cv

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ulsa Tech